Isenberg Ventures

Our unique model combines first access and proprietary rights to disruptive deal flow with an established track record of new venture formation, company building, and value creation. We invest in bold, transformative innovations to develop new drugs and technologies to improve outcomes for the market benefit of patients worldwide. Investing in early-stage venture capital We invest in seed and early-stage life science ventures, bringing Mass General Brigham’s expertise and extensive network to bear to create transformative solutions to solve unmet medical needs. Leveraging a competitive advantage Research is the driving force that advances medicine and Mass General Brigham Ventures sits at the center of the largest medical research engine in the United States. #1 in hospital medical research​ Mass General Brigham Ventures is a member of the largest hospital system-based research enterprise in the U.S., which includes Massachusetts General Hospital and Brigham and Women’s Hospital, two of the nation’s premier academic medical centers whose origins date back to the early 1800’s.​ Mass General Brigham Ventures' unique model leverages a preferred position to source technology including first access and rights to disruptive deal flow. This is an exceptional advantage that conventional venture capital funds cannot reproduce. Legacy of investing in medical innovation Mass General Brigham Ventures plays a key role in founding and funding next-generation technologies. These three transformational companies are examples of start-ups that are poised to address significant unmet medical needs. All were seeded by Mass General Brigham Ventures with founding intellectual property from Mass General Brigham. Editas Medicine: IPO Feb. 2016 (NASDAQ: EDIT) Unlocking the power and potential of CRISPR genome editing technology. CoStim Pharmaceuticals: Acquired by Novartis, Feb. 2014 Next-generation immuno-oncology drugs based on T-cell costimulatory targets. Keros Therapeutics: IPO April 2020 (NASDAQ: KROS) Novel treatments for patients suffering from hematologic and musculoskeletal disorders. Our investment strategy We invest in next-generation life science companies based on intellectual property created within our own research community. We seek strong co-investor syndicates to develop products across a range of categories including drugs, devices, diagnostics, and digital health.​ Initial investments are directed at the seed and Series A stages, where our participation attracts capital and talent into the most difficult-to-fund phase of company development. When we invest, we expect to support each portfolio company through its entire financing lifecycle. In addition to providing the necessary venture capital, we leverage our experience in starting and growing companies, our expertise in the medical industry, and our network of scientific and business talent to build great companies. Leveraging a proven approach:The annual output of high-impact invention and discovery represents a unique opportunity to create, finance, and monetize new life science-based companies. We deploy start-up capital to capture the collective expertise of our unrivaled base of scientific talent and clinical resources to bring cutting-edge science to patients Competitive advantage of Mass General Brigham: The power of collective impact from our vast research enterprise provides an unrivaled competitive advantage to build next generation life science companies capable of bringing innovative therapeutics to patients in need and delivering outstanding returns to our investors. Academic medical centers: We source deals from our five research and teaching hospitals, which collectively represent the largest teaching affiliate of Harvard Medical School.

Our portfolio includes companies at all stages of development, from early-stage companies testing transformative technologies to commercial-stage companies seeking additional growth. With a focus on areas with significant unmet need, Vertex seeks to build great companies that improve the health and quality of human life. We take an active role in our portfolio companies and work with exceptional entrepreneurs, industry partners and fellow venture investors to create value. Our global investment professionals bring deep scientific, medical and business knowledge to every investment we make. In an increasingly globalized economy, Vertex Ventures HC offers global expertise to companies around the world. With offices in Silicon Valley and Singapore, our investment team scouts and invests in promising companies in the U.S., Asia and beyond. Our team, along with our network of scientific advisors and venture partners, has deep local networks and capabilities in both emerging and established markets. Our agile structure means we can act quickly on investment opportunities.

A disciplined healthcare venture capital strategy driven by an unrelenting work ethic to achieve success for our entrepreneurs and investors. What do we look for?Innovations that deliver meaningful improvements to patient outcomes and reduce health system costs Groundbreaking opportunities in our sectors of focus: medical devices, life sciences tools & diagnostics, tech-enabled care delivery, and pharma adjacencies Founders and CEOs with domain expertise who embrace capital efficiency and seek collaborative investment partners rather than passive financiers Investments that span development and commercial stage but focus on Series A and B opportunities Under-ventured opportunities, as it relates to geographies, teams, and sectors What do we commit to you?Active and involved healthcare investors who operate with integrity, approachability, and transparency A team of passionate healthcare and venture capital experts diverse in demographic and experience A track record of success and experience navigating the ups and downs of early-stage company building Access to a world-class advisory board to leverage C-level experience, expertise, and leadership in healthcare A commitment to teamwork Since our founding in 2002, Arboretum has become a leader in early healthcare investing by fostering a culture rooted in respect and integrity. We attribute our success to the fundamental values that drive our culture. True to the missionInvest in great people with great ideas and a passion for improving healthcare quality, access, and affordability People firstLead selflessly and act as supportive partners to our entire team and stakeholders Honesty winsAct with integrity and make the hard decision when we know it is the right decision Continuous improvementStrive to be at the forefront of healthcare industry trends through research, education, and partner-building Community-focusedUse our talent, time, and resources to give back to the healthcare ecosystem and local communities The impact Community requires teamwork, and at Arboretum, we believe the best teams are diverse in culture, gender, thought, and experience. At our firm and within our portfolio companies, our goals are to be healthcare investors who: Build and foster a supportive and diverse corporate culture Prioritize diversity among senior management and fellow board members Assist our institutional investors in extending their internal diversity and inclusion initiatives

Backed by a grant from the U.S. Economic Development Administration, RightHill Ventures works in partnership with Brown, the University of Rhode Island, and other higher education institutions and their alumni to identify and fund the innovators who are developing solutions to some of the world's most challenging problems. Established by the Slater Technology Fund, a regional seed investor with deep roots in the Brown ecosystem, RightHill Ventures recruits key players from the national pool of industry and entrepreneurial talent – individuals from the broadest community – to prove our potential, build teams, and help us fuel them through early milestones. We believe that the power of university research, coupled with RightHill’s tight focus and the strength of the larger community, will result in bold launches powered by individualized investment syndicates. Leveraging Our Network of Partners Our deep ties to Brown and URI's scientific, engineering, and clinical faculty, as well as to all elements of their-and the region's-entrepreneurial ecosystem, allow us to identify the most promising innovations and connect them with the right resources to help them grow into successful companies.

When we founded the firm in 2007, our imaginations were on fire with the possibility of translating scientific discoveries to breakthrough medicines. Could we finally find cures for cancer? Would we be able to diagnose diseases before they even appear? How far could we go in restoring hope and quality of life to patients with incurable conditions? We dared to believe that nothing was impossible. To achieve what hadn’t been done before, we created a process that hadn’t been done before. By starting with big ideas and fostering collaboration among brilliant people with expertise in science, medicine, business and strategy, we set out to do more than fund startups – we aim to build sustainable, innovative companies that can transform the lives of patients. Discover Our Discovery effort is a collaborative and iterative process. We look for emerging fields of science and medicine where the time is right for us to bring transformative change to areas of unmet medical need. Working with leading scientific founders and expert advisors, we then develop a clear vision and strategy for a company with the patient front and center. With 12 years and over 50 companies worth of experience, we have created an industry-leading and differentiated approach to bring breakthrough science to patients. Launch Once a company concept has been refined and optimized through our Discovery process, we Launch the company with the necessary financial, technical and human resources to enable it to reach milestones critical for its growth and success. We become active members of the company’s leadership team, serving in interim roles to ensure the execution of the company’s R&D strategy, and to build a world-class team that shares the company’s scientific vision. Importantly, we work to establish a dynamic and innovative culture at launch where the growing team has a unified passion and commitment to make a difference in the lives of patients. Build Next, we Build on that foundation. We transition out of our interim roles and establish experienced and motivated management teams. As board members and domain experts, we work with these teams for as long as is needed to relentlessly execute on the strategy, bringing whatever resources are required from within the firm to deliver on our commitment to patients. An important element is the work we do to cultivate future partnerships and drive value creating transactions. Our companies also have access to our Beyond Great learning community, which provides peer-to-peer networking for leaders across the portfolio as well as tools and resources focused on shared elements of building successful and sustainable companies. Transform Our companies are now bringing products to patients – Transforming their lives, and the lives of their families. Third Rock portfolio companies have now launched 16 products. It is this that we are most proud of, as it means we are delivering on our mission of creating great companies that discover and develop products that make a difference for the patients we serve. Mission & Core Values Third Rock's mission is to be the preferred partner for entrepreneurs, investors, employees and industry to build great companies that discover and develop products that make a difference for the patients we serve. Integrity: always do the right thing Attitude: nothing is impossible Patients: making a difference through breakthroughs in medicine Partners: make them raving fans Organization: great people, great culture, great accomplishments Entrepreneurs: passionately innovate, found, build, have fun

A US-focused venture capital firm investing in and supporting pre-seed and seed companies. Our first fund, AI Health Fund I, will be focused on companies that use automation such as artificial intelligence to solve inefficiencies in biotech, pharma, medtech, and diagnostics. What we look forPotential: TAM of $5B+ Impact: Creates solutions that can make healthcare more accessible and affordable Differentiation: A patentable "secret sauce" Scalable Business Model: Solving a major pain point with a clear monetization strategy Market Fit: There is a proven need for the solution that the company is providing Top-Notch Team: An experienced team with complimentary skills in healthcare, business, and execution Defensible Product: Network effects, unique industry knowledge, and patentability We build and invest in iconic companies to make healthcare BETTER While offering a differentiated suite of services to our portfolio companies: The Intelligence Network: Vital support for growth & recruitment Corporate Development + M&A Advisory: We've partnered with expert bankers to achieve optimal exit opportunities Fundraising Consultation: Capital raise, investor relations, & corporate communications support Industry Analyses: Ad-hoc market intelligence and reporting to ensure our portfolio is best-in-class